Sema4D correlates with tumour immune infiltration and is a prognostic biomarker in bladder cancer, renal clear cell carcinoma, melanoma and thymoma

References

• Hall KT, Boumsell L, Schultze JL, et al. Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc Natl Acad Sci U S A. 1996;93(21):11780–11785.
   PubMed Web of Science ®Google Scholar
• Furuyama T, Inagaki S, Kosugi A, et al. Identification of a novel transmembrane semaphorin expressed on lymphocytes. J Biol Chem. 1996;271(52):33376–33381.
   PubMed Web of Science ®Google Scholar
• Giraudon P, Vincent P, Vuaillat C. T-cells in neuronal injury and repair: semaphorins and related T-cell signals. Neuromolecular Med. 2005;7(3):207–216.
   PubMed Web of Science ®Google Scholar
• Bougeret C, Mansur IG, Dastot H, et al. Increased surface expression of a newly identified 150-kDa dimer early after human T lymphocyte activation. J Immunol. 1992;148:318–323.
   PubMed Web of Science ®Google Scholar
• Mizui M, Kumanogoh A, Kikutani H. Immune semaphorins: novel features of neural guidance molecules. J Clin Immunol. 2009;29(1):1–11.
   PubMed Web of Science ®Google Scholar
• Zhu L, Stalker TJ, Fong KP, et al. Disruption of SEMA4D ameliorates platelet hypersensitivity in dyslipidemia and confers protection against the development of atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29(7):1039–1045.
   PubMed Web of Science ®Google Scholar
• Mou P, Zeng Z, Li Q, et al. Identification of a calmodulin-binding domain in Sema4D that regulates its exodomain shedding in platelets. Blood. 2013;121(20):4221–4230.
   PubMed Web of Science ®Google Scholar
• Lu Q, Dong N, Wang Q, et al. Increased levels of plasma soluble Sema4D in patients with heart failure. PLoS One. 2013;8(5):e64265.
   PubMed Web of Science ®Google Scholar
• Ishida I, Kumanogoh A, Suzuki K, et al. Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: implications for the regulation of immune and inflammatory responses. Int Immunol. 2003;15(8):1027–1034.
   PubMed Web of Science ®Google Scholar
• Kikutani H, Kumanogoh A. Semaphorins in interactions between T cells and antigen-presenting cells. Nat Rev Immunol. 2003;3(2):159–167.
   PubMed Web of Science ®Google Scholar
• Li M, O’Sullivan KM, Jones LK, et al. Endogenous CD100 promotes glomerular injury and macrophage recruitment in experimental crescentic glomerulonephritis. Immunology. 2009;128(1):114–122.
   PubMed Web of Science ®Google Scholar
• Conrotto P, Valdembri D, Corso S, et al. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood. 2005;105(11):4321–4329.
   PubMed Web of Science ®Google Scholar
• Basile JR, Castilho RM, Williams VP, et al. Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. Proc Natl Acad Sci U S A. 2006;103(24):9017–9022.
   PubMed Web of Science ®Google Scholar
• Basile JR, Holmbeck K, Bugge TH, et al. MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J Biol Chem. 2007;282(9):6899–6905.
   PubMed Web of Science ®Google Scholar
• Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer. 2008;8(8):632–645.
   PubMed Web of Science ®Google Scholar
• Flannery E, Duman-Scheel M. Semaphorins at the interface of development and cancer. Curr Drug Targets. 2009;10(7):611–619.
   PubMed Web of Science ®Google Scholar
• Ch’ng ES, Kumanogoh A. Roles of Sema4D and Plexin-B1 in tumor progression. Mol Cancer. 2010;9:251.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang J, Li H, et al. Association between prognosis and SEMA4D/Plexin-B1 expression in various malignancies: a meta-analysis. Medicine (Baltimore). 2019;98(7):e13298.
   PubMed Web of Science ®Google Scholar
• Kato S, Kubota K, Shimamura T, et al. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Cancer Sci. 2011;102(11):2029–2037.
   PubMed Web of Science ®Google Scholar
• Jiang H, Chen C, Sun Q, et al. The role of semaphorin 4D in tumor development and angiogenesis in human breast cancer. Onco Targets Ther. 2016;9:5737–5750.
   PubMed Web of Science ®Google Scholar
• Zhou H, Kann MG, Mallory EK, et al. Recruitment of Tiam1 to Semaphorin 4D activates rac and enhances proliferation, invasion, and metastasis in oral squamous cell carcinoma. Neoplasia. 2017;19(2):65–74.
   PubMed Web of Science ®Google Scholar
• Zhang C, Qiao H, Guo W, et al. CD100-plexin-B1 induces epithelial-mesenchymal transition of head and neck squamous cell carcinoma and promotes metastasis. Cancer Lett. 2019;455:1–13.
   PubMed Web of Science ®Google Scholar
• Yang YH, Buhamrah A, Schneider A, et al. Semaphorin 4D promotes skeletal metastasis in breast cancer. PLoS One. 2016;11(2):e0150151.
   PubMed Web of Science ®Google Scholar
• Sierra JR, Corso S, Caione L, et al. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med. 2008;205(7):1673–1685.
   PubMed Web of Science ®Google Scholar
• Ch’ng E, Tomita Y, Zhang B, et al. Prognostic significance of CD100 expression in soft tissue sarcoma. Cancer. 2007;110(1):164–172.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang L, Pan Y, et al. Over-expression of semaphorin4D, hypoxia-inducible factor-1alpha and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer. IJMS. 2012;13(12):13264–13274.
   Google Scholar
• Campos M, DE Campos SGP, Ribeiro GG, et al. Ki-67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas. Respectively. Oncol Lett. 2013;5(5):1527–1535.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang L, Lv R, et al. Overexpression of Semaphorin4D indicates poor prognosis and prompts monocyte differentiation toward M2 macrophages in epithelial ovarian cancer. Asian Pac J Cancer Prev. 2013;14(10):5883–5890.
   PubMedGoogle Scholar
• Liu H, Yang Y, Xiao J, et al. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients. Microvasc Res. 2014;93:1–8.
   PubMed Web of Science ®Google Scholar
• Zhang D, Li Z, Zhang R, et al. Identification of differentially expressed and methylated genes associated with rheumatoid arthritis based on network. Autoimmunity. 2020;53(6):303–313.
   PubMed Web of Science ®Google Scholar
• Besliu A, Banica L, Predeteanu D, et al. Peripheral blood lymphocytes analysis detects CD100/SEMA4D alteration in systemic sclerosis patients. Autoimmunity. 2011;44(5):427–436.
   PubMed Web of Science ®Google Scholar
• Kumanogoh A, Suzuki K, Ch’ng E, et al. Requirement for the lymphocyte semaphorin, CD100, in the induction of antigen-specific T cells and the maturation of dendritic cells. J Immunol. 2002;169(3):1175–1181.
   PubMed Web of Science ®Google Scholar
• Kumanogoh A, Watanabe C, Lee I, et al. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity. 2000;13(5):621–631.
   PubMed Web of Science ®Google Scholar
• Herold C, Bismuth G, Bensussan A, et al. Activation signals are delivered through two distinct epitopes of CD100, a unique 150 kDa human lymphocyte surface structure previously defined by BB18 mAb. Int Immunol. 1995;7(1):1–8.
   PubMed Web of Science ®Google Scholar
• Herold C, Elhabazi A, Bismuth G, et al. CD100 is associated with CD45 at the surface of human T lymphocytes. Role in T cell homotypic adhesion. J Immunol. 1996;157:5262–5268.
   PubMed Web of Science ®Google Scholar
• Billard C, Delaire S, Raffoux E, et al. Switch in the protein tyrosine phosphatase associated with human CD100 semaphorin at terminal B-cell differentiation stage. Blood. 2000;95(3):965–972.
   PubMed Web of Science ®Google Scholar
• Evans EE, Jonason AS, Jr.,Bussler H, et al. Antibody blockade of semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies. Cancer Immunol Res. 2015;3(6):689–701.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110.
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174.
   PubMed Web of Science ®Google Scholar
• Aran D, Sirota M, Butte AJ. Systematic pan-cancer analysis of tumour purity. Nat Commun. 2015;6:8971.
   PubMed Web of Science ®Google Scholar
• Danaher P, Warren S, Dennis L, et al. Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer. 2017;5:18.
   PubMed Web of Science ®Google Scholar
• Mahon FX. Treatment-free remission in CML: who, how, and why? Hematol Am Soc Hematol Educ Program. 2017;2017(1):102–109.
   PubMedGoogle Scholar
• Liang Z, Li X. Identification of ANXA1 as a potential prognostic biomarker and correlating with immune infiltrates in colorectal cancer. Autoimmunity. 2021;54(2):76–87.
   PubMed Web of Science ®Google Scholar
• Shi S, Ye S, Mao J, et al. CMA1 is potent prognostic marker and associates with immune infiltration in gastric cancer. Autoimmunity. 2020;53(4):210–217.
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73(12):3591–3603.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71(10):3540–3551.
   PubMed Web of Science ®Google Scholar